Designed for Precision.
Developed for Life.
Adcendo ApS is a global clinical-stage biotech company dedicated to developing highly differentiated first and best-in-class antibody-drug conjugates (ADCs) for targeted treatment of cancer.
Latest News
Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting
ADCE-T02 - a potential first and best-in-class topoisomerase-1 (Topo-1) inhibitor-based Antibody-Drug Conjugate (ADC) against Tissue Factor - demonstrates strong and broad preclinical efficacy and good tolerability ADCE-D01 - a first-in-class ADC against urokinase...
Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Healthcare pioneer Laura Shawver, Ph.D. appointed Chair of the Board and industry veteran RoyBaynes M.D., Ph.D. appointed as independent, non-executive Director Fang Z. Ni, Pharm.D. named Chief Financial Officer Company expands global footprint by establishing U.S....
Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors Phase I Tiffany-01 trial is designed to evaluate the safety, pharmacokinetics,...